BIOMAT Database Logo BIOMAT Database Logo

Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. 2015

S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Louis-APHP, Paris, France INSERM U941, Université Paris Diderot, Sorbonne Paris Cité, Paris, France sebastien.gallien@sls.aphp.fr.

OBJECTIVE Efavirenz and nevirapine failure is associated with a rapid selection of resistance-associated mutations (RAMs), which may impact on etravirine or rilpivirine susceptibility. However, RAMs for rilpivirine and etravirine cannot be reported on previous resistance genotypes because these specific RAMs were not analyzed at that time. Therefore, our objective was to determine, in virologically suppressed HIV-1-infected individuals, the presence of RAMs to rilpivirine, etravirine and the combination of tenofovir/emtricitabine/rilpivirine in HIV-1 DNA from individuals previously exposed to efavirenz and/or nevirapine. METHODS The studied population included 169 treatment-experienced individuals enrolled in the ANRS 138-EASIER trial who previously failed on and/or were intolerant to efavirenz and/or nevirapine and who had plasma HIV-1 RNA<400 copies/mL. Resistance to rilpivirine, etravirine, tenofovir and emtricitabine by bulk sequencing was performed on extracted HIV-1 DNA from whole blood collected at the time of trial inclusion. RESULTS Reverse transcriptase gene amplification was successful in 128/169 (76%) individuals and 95% of HIV-1 were infected with subtype B. Rilpivirine RAMs were detected in 41 (32%) individuals, with highest frequency for the mutations Y181C/I/V (18%), K101E/P (7%) and E138A/G/K/Q/R/S (6%) and the association L100I+K103N/S (5%). Etravirine RAMs were detected in five (4%) individuals. Resistance to emtricitabine, tenofovir and at least one drug included in the combination of tenofovir/emtricitabine/rilpivirine were detected in 72 (56%), 12 (9%) and 88 (69%), respectively. CONCLUSIONS In individuals with suppressed viraemia under antiretroviral therapy (ART), but who had been previously exposed to an efavirenz and/or nevirapine-based regimen, rilpivirine RAMs are frequent and etravirine RAMs are rare. This finding suggests that the switch to a rilpivirine-based regimen should not be recommended.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes

Related Publications

S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
January 2019, Infectious diseases (London, England),
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
August 2018, AIDS research and human retroviruses,
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
September 2014, AIDS (London, England),
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.
January 2010, AIDS (London, England),
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy.
January 2014, AIDS (London, England),
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
June 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
November 2008, The Journal of antimicrobial chemotherapy,
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
August 2012, Antimicrobial agents and chemotherapy,
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.
January 2010, Acta clinica Belgica,
S Gallien, and I Charreau, and M L Nere, and N Mahjoub, and F Simon, and N de Castro, and J P Aboulker, and J M Molina, and C Delaugerre
Rilpivirine resistance associated mutations in HIV-1 infected pregnant women.
January 2015, Enfermedades infecciosas y microbiologia clinica,
Copied contents to your clipboard!